Livzon Pharmaceutical (000513) Q1 2025 earnings summary

Executive summary

• Net profit attributable to shareholders rose 4.75% year-over-year to ¥636.71 million in Q1 2025.

• Revenue decreased by 1.92% year-over-year to ¥3.18 billion.

• Basic and diluted EPS increased 9.23% year-over-year to ¥0.71.

Financial highlights

• Operating cash flow dropped 21.59% year-over-year to ¥724.73 million.

• Total assets at quarter-end were ¥24.49 billion, up slightly from year-end.

• Shareholders' equity reached ¥14.17 billion, up from ¥13.86 billion at year-end.

• Non-recurring gains included ¥37.82 million in government subsidies.

Key financial ratios and metrics

• Weighted average ROE increased by 0.30 percentage points to 4.55%.

• Gross margin improved as cost of sales declined more than revenue.